INVESTORS
Market Opportunity
The Pharmaceutical market has been using the same old analytical technology for 35-40 years. The processes utilizing that technology encompass all steps in a drug's life cycle, from early R&D ("Discovery") through clinical trials, Process R&D, and finally into production.
The pain from this aging tool comes mostly in time - it takes a scientist or engineer 8-24 hours to get actionable data. That is especially cumbersome, as the numerous layoffs create a need for increased productivity in the labs, and the current technology simply cannot meet this demand. They are begging for ways to replace the old with something that saves time while equaling or improving their data for use in AI applications.
The opportunity for Novilytic is that Pharma spends >$4B per year on analytical analysis of protein-based drugs (i.e. "large molecule"). More importantly, they spend, literally, years testing. Our multi-patented technologies allow these scientists to do in <15minutes what takes them hours and days to do now. Early and advanced platform pilot tests at 5 of the top 25 Pharma and CDMO companies are proving that to be true. Some, like J&J (Johnson & Johnson/Janssen Pharmaceuticals), have published peer-reviewed articles and presentations that confirm the same. So now Novilytic is poised to replace that $4B consumables stream with our truly disruptive technology.
Market and Commercialization Strategy
Our marketing strategy is focused on addressing the largest and most immediate need first. That concentration is in the Discovery, Clone Selection, and Process R&D. This is also the department where the most testing goes on - they are running millions of tests per year. As the Proteometer is a consumable that replaces the old consumables, the potential for dramatic growth is extremely large.
The tactical efforts of our marketing strategy will focus on top-down and bottom-up calls for action related to saving time and ease of use. We will highlight that the Proteometer not only saves hours and days, but it also offers better accuracy. Secondly, we will focus on its “plug and play” nature and the use of existing tools and software already owned and used daily throughout all stages of the pharmaceutical development process.
The go-to-market strategy will utilize major instrument and distributor channels that can sell more of their products with our technology, making our technology sales-enhancing versus just another tool.
All manufacturing will be completed at GMP and ISO-validated suppliers to complement our similar assembly strategy. Combined, this focus will ensure way-above-average profits and an expeditious expansion into the market.
Technical and Competitive Advantage
The Proteometer is a platform that utilizes nanoparticles and other small molecular ligands with affinity for specific structural components of proteins. The first three versions of our platform address the top three needs, as advised by the market. Our next three versions, in response to market demand, will be released over the next six to nine months, arriving in Q1 and Q2 of 2026. We will then continue to grow versions for new markets, including animal analytics, mNRA, DNA, and food-based protein markets.
The utilization of our patented nanotechnology is not available from any other source. To ease its use, the Proteometer (a.k.a. Proteoform Meter) has been tested and approved for use by four of the top five global instrument companies. Then its utility was confirmed in pilots at multiple major leading pharmaceutical companies. Two of them (Pfizer and J&J) then published peer-reviewed articles and presentations on the Proteometer.
Artificial Intelligence Opportunities
The use of the Proteometer yields significant data essential to the target market. The consumable kit plugs into existing instruments that have their proprietary AI or push the data to other approved AI used by the scientists. Our strategic advantage in this situation is that we provide much more accurate data significantly faster than their current methods. That ensures pharmaceutical scientists do not fall into the "garbage in, garbage out" category by using our technology. A significant benefit to Novilytic is that pharmaceutical companies do not have to spend one to two years learning, testing, and security-checking a new software. They use what they already have, albeit with much better data.
Regulatory Strategy and Intellectual Property
The use of the Proteometer does NOT require any FDA or other regulatory approval. The Proteometer is first being adopted in pharma discovery, clone selection, and process R&D departments that do not have regulatory restrictions. If it is utilized in manufacturing, it will be part of the pharma company's FDA submittal. As >90% of the target instruments are outside of manufacturing, regulatory approval is not a significant part of our IP Go-to-Market strategy. Our IP includes multiple methods and concept of matter patents which combine to create a protective mote from outside duplication. We currently have additional patents pending with similar strategies.